SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-017024
Filing Date
2024-04-29
Accepted
2024-04-29 16:45:16
Documents
15
Period of Report
2024-04-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 50681
2 ex10-1.htm EX-10.1 27318
  Complete submission text file 0001493152-24-017024.txt   314825

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tenku-20240426.xsd EX-101.SCH 4090
4 XBRL DEFINITION FILE tenku-20240426_def.xml EX-101.DEF 27618
5 XBRL LABEL FILE tenku-20240426_lab.xml EX-101.LAB 38290
6 XBRL PRESENTATION FILE tenku-20240426_pre.xml EX-101.PRE 26235
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 7233
Mailing Address 420 LEXINGTON AVE, SUITE 2446 NEW YORK NY 10017
Business Address 420 LEXINGTON AVE, SUITE 2446 NEW YORK NY 10017 (347) 627-0058
TenX Keane Acquisition (Filer) CIK: 0001851484 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41534 | Film No.: 24891967
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)